C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
Open Access
- 9 April 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 145 (1), 73-82
- https://doi.org/10.1007/s10549-014-2933-7
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cellsBreast Cancer Research and Treatment, 2012
- CXCR3 ligands: redundant, collaborative and antagonistic functionsImmunology & Cell Biology, 2011
- CXCR3/Ligands Are Significantly Involved in the Tumorigenesis of Basal Cell CarcinomasThe American Journal of Pathology, 2010
- CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma CellsCancer Research, 2007
- CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival.2006
- The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell linesImmunology Letters, 2004
- Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3The Journal of Experimental Medicine, 1998
- Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases.The Journal of Experimental Medicine, 1996
- IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo.The Journal of Experimental Medicine, 1993
- Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells.The Journal of Experimental Medicine, 1993